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Introduction
Growth factors were discovered when investigators studied biological substance effects 
on cells and tissues in cultures, identified an assembly of substances that were peptide-
hormone-like which were different from any hormones previously known. The similarity of 
growth factors with hormones is that some growth factors can be secreted into the blood 
stream, transporting them to their tissues. However, the production of hormones is strictly 
limited to glandular tissue. On the other hand, many types of tissues can produce different 
types of growth factors. An example of a class of signaling proteins that can act as growth 
factors are cytokines. They are used widely in cellular communication, in the function of 
the immune system, and in embryogenesis. In the past, growth factors and cytokines were 
thought to respectively serve as cell growth components and immunological response 
factors [1]. Most recently, research has stated that growth factors for example cytokines 
can have similar functions and can be used interchangeably. There are several different cell-
signaling mechanisms are used to best suite its purpose. Paracrine signaling occurs between 
neighboring cells where the signals get quick responses and last only a short amount of time 
due to the degradation of the paracrine ligands [2,3]. In autocrine signaling, a cell signals itself 
through a component that synthesizes, leading to a biological response within the same cell. In 
endocrine signaling, growth factor and cytokine components are secreted into the blood and 
are then carried by blood and tissue fluids on to target cells where by subsequent responses 
are triggered [3]. Growth factors can also be divided into various families or super families 
based on structural and functional characteristics. An example of a major growth factor family 
is the transforming growth factor-β (TGF-β superfamily). TGF-β was originally characterized 
as a protein that was capable of inducing a transformed phenotype in non-neoplastic cells in 
culture. In TGF-β, all the family members have dimeric structures and their heterodimeric 
receptor complexes are consisted of type I and type II receptor subunits with serine/
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Abstract
Growth factors are found in most of the organisms including insects, humans, plants, etc. The name ‘growth 
factors’ became known when the substances were active in stimulating the growth of cells and tissues. 
Growth factors are regulatory species (signaling molecules mainly proteins) that are generated by the 
body which function in binding to receptors on the cell surface and are required to stimulate the growth 
in living responsive cells by triggering cellular proliferation and/or cellular differentiation pathways, 
as well as by regulating gene transcription in the nucleus.  They are quite versatile by promoting cell 
growth and act in a paracrine, retrocrine, autocrine, or juxtacrine signaling pathways. Cellular division 
is stimulated by growth factors in different cell types, while others can be specific to a cell type. Every 
growth factor binds to a specific receptor on the cellular surface. Cytokines are a family of growth 
factors that help in stimulating the movement of cells towards inflammatory sites, trauma, and infection. 
Abnormal regulation and production of growth factors and cytokines tends to cause various diseases that 
include, but are not limited to, cancer, diabetes, liver fibrosis, and bronchopulmonary dysplasia.  A critical 
discussion with a focus on the diverse role and abundance of front-line growth factors in human body is 
presented. Bio-pharmacological relationships between growth factors with several diseases have also 
been incorporated in this article.
Keywords: Growth factors; Cell proliferation; Cellular differentiation; Cytokines; Fibroblast
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threonine kinase domains. Within the family, complex interaction 
remains the same. Following ligand binding, the type I receptor 
is phosphorylated and stimulated by the type II receptor, which 
then activates a Smad-dependent signaling pathway, regulating 
gene transcription [3]. For research purposes, growth factors are 
used in cell models to study their functions, and their signaling 
pathways. Based on their roles, many growth factors in cytokines 
have also been utilized for preclinical and clinical applications. 
Recombinant human platelet-derived growth factor (PDGF) is an 
example of a growth factor, made by platelets in blood clots, and 
has been used to stimulate angiogenesis, migration, and mitosis 
in mesenchymal cells in preclinical studies. Although clinical 
applications of cytokines are considered as standard treatment for 
certain diseases but there are also side effects associated with this 
treatment. As an example, the administration of granulocyte-colony 
stimulating factor (G-CSF) has been reported to cause osteoporosis, 
acute coronary syndrome, and bone marrow necrosis. High 
quality growth factors must pass various quality control testing 
for purity, quantification, and activity. Purity tests, such as SDS-
PAGE can determine the possible contamination with non-specific 
proteins, and/or endotoxins that can trigger undesirable effects 
such as cell differentiation. Quantification is used to achieve 
product size and results. Commonly used protein quantification 
methods are Bradford colorimetric dye, UV-visible spectroscopy, 
and Densitometric comparison. Growth factor activity is tested 
through specific bioassays that determine the relative strength of 
the growth factor to a standard [1-3].
Growth Factors: Major types
There are various kinds of growth factors that exist, and several 
were initially isolated from animal tissues, including cattle and 
mice. Insulin-like growth factors are examples of these substances 
because they stimulate growth by growth hormone secretion from 
the pituitary gland; the epidermal growth factor, which stimulates 
the growth of epidermal cells; the nerve growth factor, which 
stimulates the growth of neuronal cells, and lastly, the platelet-
derived growth factor, which stimulates the growth of connective 
tissue cells and also muscle cells. Insulin-like growth factor I is also 
called somatostatin C, IGF-I. This hormone is widely discussed for 
possible performance enhancement and shares the common name 
“insulin” which is the medication used to treat type I diabetes [4]. 
The secretion of IGF-I is regulated by human growth hormone, 
which is produced by the pituitary gland. IGF-I is produced, 
secreted primarily from the liver. There are other peripheral tissues 
such as bone, that produces its own IGF-I. The reason behind 
the name of IGF-I is that it has insulin like subunit that binds to 
insulin receptors, but it only has 10% of the potency of regular 
insulin on glucose regulation. Insulin-like growth factor I (IGF-1) 
is an anabolic hormone, meaning it promotes growth. It includes 
skeletal muscle and it is not androgenic, as opposed to testosterone 
which indicates that it does not promote male sex characteristics 
such as facial hair, deep voice, etc. The side effects of IGF-I are low 
blood sugar, retinal edema, severe muscle pain, and bell’s palsy 
[1,4]. Figure 1 summarizes the relationship of IGF-1 with various 
cellular/physiological processes.
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Figure 1: Multidirectional functions of Insulin-like growth factor 1 (IGF-1).
Growth factors play key roles in human body. The major 
primary effect is growth stimulation; it affects all tissues equally in 
the body, not just skeletal muscle, and occurs because it is released 
in the blood stream by the liver. Other functions include whole body 
protein synthesis, and inhibition of protein breakdown, low blood 
sugar, increased kidney filtration, enhanced bone mineralization, 
and more. Its function overlaps with human growth hormone 
(HGH). HGH is a hormone that is responsible for the production of 
growth factors and perform various functions in the human body 
including developmental and operational functions. After maturity, 
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approximately around age 20, the HGH that the body produces 
declines naturally and dramatically, but HGH is still necessary during 
adulthood in order for growth, cellular repair and regeneration to 
occur. However, HGH is not a good performance enhancer because a 
recent study found where the supplementation of growth hormone 
is no more effective at skeletal muscle growth than a placebo. The 
side effects of HGH include arthralgia, arthritis, enhanced heart, 
muscle weakness, high cholesterol, impaired glucose regulation and 
increased risk of type I diabetes, impotence, and increased fatigue 
[4]. As it has been mentioned earlier, growth factors act as typical 
signaling proteins and are also capable to regulate/contribute in 
several dreadful diseases like cancer, diabetes, HIV, cardiovascular 
diseases and so on. A brief account elaborating the influences of 
growth factors on these diseases are presented in the sequel.
Role of growth factors in Cancer
Growth factors frequently are involved in the production 
of resistance to therapeutic procedures, prolonging the role of 
polypeptide factors to precise late stages of tumor development 
and offering opportunities for cancer therapy.  Studies done in the 
early 1950’s were one first occurring lines of evidence regarding 
cancer with soluble growth factors. The mechanisms that allow limb 
innervation in chick embryos, and transplanted a lump sarcoma 
found on a mouse onto an embryo were studied by observing 
thorough attraction of nerve fibers to the sarcoma lump. Later, a 
venom from a snake was identified and the murine submaxillary 
gland secreted a particularly active “nerve-stimulating factor”, that 
began with the isolation of the first growth factors: Nerve Growth 
Factor (NGF) and Epidermal Growth Factor (EGF). It was reported 
that cells that were infected by the ‘feline sarcoma virus’ lost their 
ability to bind EGF, leading to the isolation of a murine sarcoma of 
two “transforming growth factors”, TGF-α and TGF-β [5,6].
Cancer drugs are the focus of intense clinical investigation. 
Angiogenesis is mainly driven by 3 angiokinase pathways and is 
critical for diseases such as solid cancers, where new blood vessels 
deliver oxygen and nutrients to tumors, enabling tumor growth 
and metastasis. Blood vessels are composed of many cell types, 
that include endothelial cells, smooth muscle cells, and pericytes. 
Three signaling molecules that activate receptor tyrosine kinases 
on pericytes, vascular smooth muscle cells, and endothelial cells 
in order to initiate important proangiogenic signaling cascades 
are fibroblast growth factor (FGF), platelet-derived growth factor 
(PDGF), and vascular endothelial growth factor (VEGF). VEGF 
and FGF stimulate endothelial cell growth migration and survival, 
critical for new blood vessel formation. PDGF stimulates pericyte 
recruitment, that is needed for normal microvascular stability 
and function. PDGF is also identical to the RNA tumor virus called 
simian sarcoma virus. PDGF and FGF stimulate smooth muscle 
cell recruitment, critical for maturation and maintenance of 
blood vessels. All three growth factors are crucial to blood vessel 
formation maintenance and integrity [5,6].
VEGF is a homodimeric glycoprotein and a predominant 
angiogenesis pathway that is a target for anticancer therapy, 
making it the most important growth factor. The reason being 
is that its angiogenesis-promoting activity is at the level of the 
endothelial cell, and tumor penetration is less critical for VEGF 
inhibitors because it is compared with agents that directly target 
tumor cells. Tumors can activate alternative or escape mechanisms, 
and can upregulate FGFR, either spontaneously or during VEGF 
blockade. The result of the “angiogenic switch” is caused by the 
production of VEGF and other growth factors by the tumor, making 
it grow exponentially and leading to high interstitial pressure. 
Many biomarkers have been recognized as prognostic effectors 
and novel metastatic markers, targeting biomarkers such as 
growth factors and chemokines in gastric cancer (GC). In addition, 
tumors overexpress FGFR and PDGFR, representing a direct target 
for growths inhibiting FGFR and/or PDGFR by blocking all three 
angiokinase pathways, and making an approach to affect tumor 
growth by inhibiting critical steps in angiogenesis, increasing 
the effectiveness of chemotherapy and radiotherapy. Through 
several studies it was suggested that triple angiokinase inhibition 
may prevent further tumor growth and related tumor escape 
mechanisms. Bevacizumab is a humanized monoclonal drug that 
is used to treat several types of cancers and is directed at VEGF, 
making it the most advanced in clinical development by making 
VEGF a rational focus for anticancer therapy, showing promising 
results in clinical trials [6,7].
About 1.6% of the 22,000 functional genes in the human genome 
display intermittent somatic mutations in cancer. It should be 
considered that genes in the pathways are due to driver mutations 
not being able to interrupt on more than one gene in a pathway. 
Few gene families inside protein kinase descends that are placed 
downstream of growth factor receptors are frequently mutated 
in certain tumors. For example, pancreatic (RAS), melanomas 
(B-RAF), brain cancer (EGFR), and breast (ErbB-2/HER2). However, 
co-existence of such mutations and driver mutations that directly 
affect growth factor genes are very rare [8].
Prostate cancer (PCa) is the most common type of cancer in 
males. Recent studies suggest patients who have diabetes and take 
metformin (MF), have a lower chance of getting PCa. MF helps by 
lowering blood glucose levels, preventing the liver from making 
additional glucose. The growth factor, IGF-1 causes production and 
growth of PCa and MF has antineoplastic effects like adenosine 
monophosphate-activated protein kinase (AMPK), which is the 
suppression of androgen signaling pathways. Conveyance of meta-
analysis proposes mortality benefit to patients who display PCa 
when taking MF, improved significantly [9].
Role of growth factors in Diabetes
Type 1 diabetic mellitus (T1DM) is known to adversely affect 
pubertal development and linear growth. Insulin-like growth 
factor-1 (IGF-I) is an extension of a growth hormone and seems 
to be associated in the earlier stages of the disease. Low levels of 
IGF may be linked to increased secretion of growth hormones in 
people with type 1 diabetes. IGF-1 is produced in the liver as an 
endocrine hormone and in target tissues. The production IGF-1 has 
the highest rates during pubertal growth spurt and have the lowest 
levels in infancy and old age. The growth hormone concentration 
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in people who have diabetes are generally 3 to 4 times higher than 
people who do not have the disease. Abnormal levels of IGF and 
growth hormones may also increase the chances and complications 
of diabetes. Growth hormone has a pulsating secretion with age-
dependent concentrations that are characterized by mediocre 
secretion in the pre-pubertal period, a rise at puberty, and a 
reduction in old age. Results of clinical trials evaluating IGF-1in 
both type 1 and type 2 diabetes showed a great result in reduction 
of hemoglobin A1C levels, and daily insulin consumption. Insulin-
like growth factor-binding protein (IGFBP-3) is an abundant protein 
that is encoded by the IGFBP3 gene and is the most important ICFP 
circulating during early age and is growth hormone dependent. 
IGFBP-3 carries IGFs to the target tissues and prolongs the half-
life of IGFs, making a ternary complex with acid labile subunit 
(ALS), which have an important role in the management of skeletal 
growth. Studies have shown and proved that insulin regulates 
the hepatic growth hormone receptor expression to influence the 
serum concentrations of IGFs and IGFBPs [4,10,11].
The structural changes that characterize diabetic 
microangiopathy ‘abnormal growth’ and ‘impaired regeneration’ 
strongly suggest a role for several irrationally expressed 
growth factors that can possibly lead to the development of the 
complications. Increased concentrations have been detected and 
have occurred in some growth factors targeting tissues of long-
term diabetic complications, enhancing the expression of the 
growth factors. They activate the biochemical pathways that link 
hyperglyceaemia to microvascular changes: vasoactive hormones; 
hyperglyceaemia pseudohypoxia; non-enzymatic glycation of 
proteins; oxidative stress, and the polyol pathway. The transforming 
growth factors beta (TGF-βs) are involved in both the early and 
late stages and is accountable for extracellular matrix (ECM) 
accumulation. VEGF, PDGF, and bFGF (basic fibroblast growth 
factor) also play crucial role in non-proliferative retinopathy as well 
as proliferative retinopathy. VEGF is the growth factor that is most 
closely correlated with neovascularization. The failure of numerous 
neurotrophic factors, IGF-I, and nerve growth factor (NGF) have 
been related to the deterioration or impaired alteration that occur 
in diabetic neuropathy. The liver is very vital in protecting you 
against diabetes. The three things that lower IGF are insulin, stress, 
and estrogen. Exercise, intermediate fasting, and sleep will trigger 
IGF [12,13].
Diabetic retinopathy can have sight-threatening complications, 
including preretinal neovascularization and chronic retinal 
oedema. Growth factors have been involved in the pathogenesis of 
ocular neovascularization because of the association with retinal 
ischaemia. The ischaemic retina secrete growth factors, stimulating 
residual vessels to grow rapidly. It has been found that many growth 
factors are manufactured during the neovascular process, resulting 
in limited effects of their specific inhibition. Laser photocoagulation 
of the retina is currently the only treatment for proliferative diabetic 
retinopathy because the regression of new vessels has been proven 
beneficial, possibly through the destruction of the ischaemic retina, 
which produces neovascular growth factors [13,14]. 
Relation between growth factors with HIV and AIDS
Human immunodeficiency virus (HIV) infection is associated 
with multiple defects in hematopoiesis and immune regulation. 
Over 36.9 million people were living with HIV/AIDS in 2017, 
which is the latest data available. 21.7 million people accessed 
antiretroval therapy (ART) in 2017 [15,16]. The deficiencies 
decrease the proliferation of hematopoietic progenitor cells (IGF-I, 
IGF-II, and IGFBP3), and a boost in the destruction of mature cells 
(IGFBP1 and IGFBP2). IGF-I levels are a warning sign because it 
increases the risk of potential adverse effects, such as malignancy 
or acromegalic-like symptoms. IGF-I levels can increase with other 
hormones such as erythropoietin for the treatment of anemia or 
anabolic androgens that have been used in other patients [17]. 
Hematopoietic growth factors are a successful approach to the 
management of clinical problems. Till date three major agents 
have been demonstrated therapeutic potential against HIV in 
clinical trials. In a phase I trial, granulocyte macrophage-colony 
stimulating factor (GM-CSF) improved pre-existing neutrophil 
defects and leukopenia in patients with HIV infection. In a placebo-
controlled trial, erythropoietin (EPO) decreased the transfusion 
requirements and corrected anemia in patients who were obtaining 
zidovudine. In a phase I/II trial, granulocyte colony-stimulating 
factor (G-CSF) also corrected neutrophil defects and leukopenia in 
patients with AIDS excluding the alteration of HIV expression. In 
both treatments, G-CSF and EPO improved leukopenia and anemia, 
reducing the toxicity of zidovudine. There have been new solutions 
of hematopoietic stimulants that are being used to compress the 
toxicity from cytotoxic chemotherapy in the treatment of AIDS-
related malignancies [17,18].
Cytokines are involved in the pathogenesis of disease 
progression and in the treatment of HIV. The primary role of 
cytokines is to regulate blood cell production and have been 
examined significantly in HIV positive patients. Granulocyte-
macrophage colony-stimulating factor (GM-CSF), Granulocyte 
colony-stimulating factor (G-CSF), and IL-3 have been classified as 
treatments to improve the count of low blood cells that accompany 
AIDS. Peripheral blood cytopenia is one indication of HIV infection 
that has a decline in blood cell counts, resulting in immune function 
weakness. CD4+ lymphocytes are one of the cell types that decrease 
in number during HIV disease breakthrough [19].
A study performed in 2016 for reciprocal effects of “antiretroviral 
drugs” were used to treat HIV infection on FGF21/β-Klotho (KLB) 
System. Antiretroviral therapy (ART) uses HIV medicines to treat 
HIV (it is not a cure for the disease) and helps people live longer and 
healthier. It is recommended for everyone who has HIV infection to 
start ART as soon possible. In antiretroviral therapy (ART), results 
showed that HIV-infected patients showed high circulating levels 
of FGF21 but in contrast, β-Klotho was reduced in target tissues, 
making HIV a chronic medical condition. The high levels of FGF21 
in HIV patients are associated with altered bone homeostasis. In 
present studies, the effects of FGF21 and KLB for antiretroviral 
treatments resulted in induction of FGF21 levels and suppression 
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of KLB expression; reflecting the effects of gene transcription. The 
alterations in the FGF21/KLB system that was found in HIV patients 
should be improved by minimizing adverse effects of antiretroviral 
agents in patients that are infected with HIV [20-23].
Growth factors and Central Nervous System (CNS)
There are quite a few major classes of growth factors which act 
within the nervous system. Fibroblast growth factors (FGFs) are a 
family of growth factor signaling proteins that have multiple roles 
and are involved in angiogenesis, embryonic development, and 
signaling pathways. They also regulate developmental processes 
and the physiology of adults. There are members of FGF that have 
multiple roles and there are partially 22 members of the FGF family. 
10 of them are expressed in the developing CNS, and within these 
10, there are four FGF receptors (FGFR-1-4). Fibroblast growth 
factors -2 and -15 are commonly expressed throughout the evolving 
CNS. FGF-8 and FGF-17 are restricted into a specific region in the 
developing brain and those two are only expressed in the embryo 
during the early phases of neurogenesis and proliferation. FGFR-
1 is the growth factor that is expressed the most, while FGFR-2 
and FGFR-3 show patterns that change expression throughout the 
central nervous system development. Most FGFs are fundamentally 
secreted using the Endoplasmic Reticulum-Golgi secretory pathway 
[24]. 
Secreted FGFs signal to target cells by binding and activating 
cell-surface tyrose kinase FGF receptors. FGFRs are transcribed 
from four different genes and consist of a single transmembrane 
domain, a cytoplasmic tyrosine kinase domain and an extracellular 
domain. There are three immunoglobin-like domains that the 
extracellular domain contains, named loops I, II, and III. Loops II 
and III attach to the bound ligand, COOH-terminal portion of loop 
III is the region that dictates binding in a specific matter. Another 
mRNA merging of the COOH-terminal portion of loop III constructs 
some forms of FGFRs with extremely unique ligand-binding 
properties. The receptor combines with a molecule to form a dimer 
and phosphorylates intermolecular tyrosine residues after an 
FGF ligand is bound, resulting in initiation trigger of FGFR signal 
transduction. The signaling of FGFR activates numerous of signal 
transduction molecules like: phospholipase C-γ pathways and Ras. 
FGF12 and FGF14 interact with the “mitogen-activated protein 
(MAP) kinase scaffold protein Islet-Brain-2 neurons” [24,25]. 
The binding of ligands is affected by distributing the heparin 
sulfate proteoglycans (HSPGs) on the cell surface and in the 
extracellular matrix. Extracellular FGFs bind firmly to HSPGs. HSPGs 
may interact with receptors on nearby cells and restrict diffusion, 
and favor interaction. Lastly, HSPGs promote and keep assembly 
in a steady state of the FGF ligand-receptor complex. Studies have 
shown that Xenopus embryos’ initiation of posterior neural tissue 
that is arbitrated by the transcription factors XBF2 and Xmeis3 
depends upon the activation of the FGF signaling-dependent-Ras-
MAP kinase pathways. Studies on chicken embryos that have shown 
that progress of posterior neural tissue is promoted by FGFs while 
maintaining the proliferating neural progenitors which contribute 
to posterior CNS development [4,24,25].
Role of growth factors in Cardiovascular Diseases
Fibroblast Growth Factors (FGFs) have recently been studied 
completely as some potentially new molecules in order to prevent 
and help treat cardiovascular disease, angiogenic actions, and 
attribute to metabolic effects. Members of the endocrine FGF 
family have been shown to increase metabolic rate, restore glucose 
homeostasis, and decrease adiposity. FGF serum levels have been 
related with well-known cardiovascular risk factors as well as with 
the severity and extent of coronary artery disease (CAD) and is also 
used to predict cardiovascular death. Clinical trials have examined 
FGF administration for therapeutic angiogenesis in ischaemic 
vascular disease. This demonstrates a possible role in order to 
improve ischaemic chest pain and limb function. Also, FGF21 
is the most recent member of the FGF family and has recently 
developed as a potent metabolic regulator with multiple effects 
that have improved the lipoprotein profile. This may be very useful 
as markers of cardiovascular risk and can work as a therapeutic/
protective agent in cardiovascular disease [26].
FGF23 is a member of the endocrine FGFs and a recent large 
study was performed where the increased FGF23 levels were 
combined with cardiovascular death, including an incident heart 
failure in 3,627 patients with stable ischemic heart disease. There 
was a better response to therapy with angiotensin-converting 
enzyme inhibitor therapy with FGF23 levels. The link of FGF23 with 
direct cardio effects, including possible connotation of serum levels 
with cardiovascular risk factors are currently still being researched 
[26,27].
Growth factors and Parkinson’s Disease 
Parkinson’s disease is a progressive and chronic disorder of the 
nervous system that affects movement of the body. It is one of the 
most frequent neurodegenerative disorders in humans. The cause 
for the disease is not clear, and no known cure has been found, but 
there are treatment options like medication and surgery in order to 
improve the symptoms. Brain-derived neurotrophic factor (BDNF) 
are critical modulators in maintenance and neurodevelopment of 
both the CNS and PNS that advocate for the survival of neuronal cells 
in production. These factors can likely be a potential therapeutic 
target in order to treat Parkinson’s disease (PD). In clinical trials, it 
has been reported that BDNF have been considered central in new 
therapeutic strategies, which can either ease or reverse the harmful 
symptoms in advanced Parkinson’s disease [28,29].
Growth factors and Alzheimer’s Disease 
Alzheimer’s disease (AD) is the most common form of dementia 
that causes problems with a decline in memory, thinking and 
behavior. Symptoms of Alzheimer’s develop slowly and worsen 
over time, making it difficult to complete daily tasks. It affects more 
than 5.5 million Americans, about 30% of elders over 75 years old 
- making it the sixth leading cause of death in the U.S. There is no 
cure for AD, but treatments and research continue [30]. Cholinergic 
basil forebrain (CBF) neurons are important in pathogenesis 
of Alzheimer’s and are very dependent on nerve growth factor 
(NGF), which has been projected as a potential therapy for AD by 
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slowing the progression of the disorder due to its effects on the 
CBF. Amyloid- β (Aβ) is known to impair communication between 
neurons, resulting in neurodegeneration. The Aβ peptides lead to 
deposition of senile plaques and decline the cognitive functions. 
Familial Alzheimer’s result from mutations in the gene for 
amyloid-β protein precursor or enzymes generated by Aβ [31]. It is 
possible for Aβ to accumulate in people with no family history of the 
disease, making the cause of intermittent AD less clear. Studies have 
shown that Aβ42 is necessary in the pathogenesis of Alzheimer’s 
due to its senile plaque deposits by increasing the expression of 
genes in neuroblastoma cells like insulin-like growth factor binding 
proteins 3 and 5 (IGFBP3/5). The IGFBP’s showed increase in vivo 
concentrations of human AD cerebrospinal fluid and are modulated 
by Aβ42, making it a beneficial early biomarker [32].
Growth factors and Chronic Kidney Diseases
FGF-19, FGF-21, and FGF-23 are three members of the fibroblast 
growth factor (FGF) family. They are endocrine factors that act in 
regulating several metabolic processes. They do not have FGFRs 
(FGF receptors), but instead have binary complexes of FGFRs and 
Klotho proteins. FGF-23 and FGF-21 are biomarkers that start to 
increase in early-stage CKD (chronic kidney disease). FGF-23 is a 
hormone that is mainly derived from bone, binding to α-Klotho, 
a transmembrane protein [22]. The physiological functions of 
FGF-23 are mediated from both FGF-23 and α-Klotho by forming 
a trimeric signaling complex, allowing to circulate and activate 
FGFR/ α-Klotho complexes permitting the renal tubules to increase 
the excretion in phosphate per neuron. In order to maintain the 
phosphate balance, a decrease in the nephron during the chronic 
kidney disease progression must be active while having an increase 
the FGF-23 necessary for compensation [22,33]. Nephron loss can 
be accelerated by inducing renal tubular damage by an increase 
in phosphate excretion per nephron [34]. CPPs (calciprotein 
particles) are a complex of calcium and phosphate nanoparticles 
that induce impairments such as endothelial damage and 
inflammatory responses [35]. CKD progression is associated by the 
increase of CPPs in the blood, resulting in cardiovascular disorders. 
Causes include CKD-MBD (CKD-mineral and bone disorder) which 
results in calcification of soft tissue due to damaged calcium and 
phosphorus metabolism. FGF-23 is elevated in CKD-MBD. FGF-21 
is a liver-derived hormone that binds to βKlotho-FGFR complex 
that is responsible for inducing stress responses in the CNS (central 
nervous system), activating the SNS (sympathetic nervous system) 
and the hypothalamus-pituitary-adrenal axis. The most effective 
way for refining clinical outcomes through enrichment of CKD-MBD 
would include surgical interventions, which would help reduce 
levels of FGF-23 and CPPs [34,35].
Growth factors and Platelet-Rich Plasma (PRP)
Growth factors might have several future implications including 
platelet-rich plasma. Platelet-rich plasma (PRP) is a substance that 
promotes soft tissue healing when injected. Platelets are important 
reservoirs of growth factors and the role of plasma is to help blood 
clotting by special factors or proteins while also supporting cell 
growth. PRP has been produced by isolating plasma from blood and 
concentrating it. A few examples of PRP injections have been used 
for hair loss, tendon injuries, acute injuries, postsurgical repair, 
osteoarthritis, and more [36-39]. The following growth factors are 
contained in the α-granules of platelets: Platelet-Derived Growth 
Factor (PDGF), Transforming Growth Factor (TGF), Platelet-Derived 
Angiogenesis Factor (PDAF), Interleukin (IL), Vascular Endothelial 
















Figure 2: Platelet-rich plasma (PRP)..
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The clinical effectiveness of platelet concentrates as: 
Autologous Platelet-Rich Plasma (APRP) depend mainly on the 
concentration of growth factors, as well as the number of platelets, 
acting as transmitters such as tissue healing and making them 
responsible for proliferation, chemotaxis, tissue morphogenesis, 
and differentiation. Studies on the effect of PRP in hair regrowth 
by injecting PRP which induced proliferation of dermal papilla cells 
by upregulating FGF-7, extracellular signal-related kinase (ERK), 
β-catenin, and Akt signaling. An important factor in hair growth 
is anagen-associated angiogenesis due to the secretion of VEGF by 
the fibroblasts of dermal papilla and keratinocytes of outer root 
sheath. By injecting the PRP into the scalp, researchers were able 
to demonstrate improvement in cutaneous ischaemic conditions, 
epidermis thickness, and an increase of hair follicles after PRP 
treatment [40-42].
Conclusion
Growth factors are part and parcel in human life. They are able 
to initiate/propagate/maintain and terminate various cellular 
mechanisms. Subsequently, growth factors play important role 
from cell division/cell growth to cell death. Although several 
research projects are being conducted around the world but more 
research is required to understand versatile roles and functions of 
growth factors in human body.
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